|
1
|
Brunt EM, Neuschwander-Tetri BA, Oliver D,
Wehmeier KR and Bacon BR: Nonalcoholic steatohepatitis: histologic
features and clinical correlations with 30 blinded biopsy
specimens. Hum Pathol. 35:1070–1082. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marchesini G, Brizi M, Morselli-Labate AM,
Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N:
Association of nonalcoholic fatty liver disease with insulin
resistance. Am J Med. 107:450–455. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Diehl AM: Lessons from animal models of
NASH. Hepatol Res. 33:138–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kita Y, Takamura T, Misu H, Ota T, Kurita
S, Takeshita Y, Uno M, Matsuzawa-Nagata N, et al: Metformin
prevents and reverses inflammation in a non-diabetic mouse model of
nonalcoholic steatohepatitis. PLoS One. 7:e430562012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCullough AJ: Thiazolidinediones for
nonalcoholic steatohepatitis - promising but not ready for prime
time. N Engl J Med. 355:2361–2363. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shah B and Shah G: Antifibrotic effect of
heparin on liver fibrosis model in rats. World J Gastrointest
Pharmacol Ther. 3:86–92. 2012.PubMed/NCBI
|
|
7
|
Howell M, Mohun TJ and Hill CS: Xenopus
Smad3 is specifically expressed in the chordoneural hinge,
notochord and in the endocardium of the developing heart. Mech Dev.
104:147–150. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saï P, Pogu S and Ouary M: Heparin
attenuates low-dose streptozotocin-induced immune diabetes in mice
and inhibits the beta-cell binding of T-splenocytes in vitro.
Diabetologia. 34:212–217. 1991.PubMed/NCBI
|
|
9
|
Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q,
Ren C, Ponomarenko A and Decarli LM: Model of nonalcoholic
steatohepatitis. Am J Clin Nutr. 79:502–509. 2004.PubMed/NCBI
|
|
10
|
Bligh EG and Dyer WJ: A rapid method of
total lipid extraction and purification. Can J Biochem Physiol.
37:911–917. 1959. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergman M and Loxley R: The determination
of hydroxyproline in urine hydrolysates. Clin Chim Acta.
27:347–349. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang HD, Pagano PJ, Du Y, Cayatte AJ,
Quinn MT, Brecher P and Cohen RA: Superoxide anion from the
adventitia of the rat thoracic aorta inactivates nitric oxide. Circ
Res. 82:810–818. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiemermann C, Ruetten H, Wu CC and Vane
JR: The multiple organ dysfunction syndrome caused by endotoxin in
the rat: attenuation of liver dysfunction by inhibitors of nitric
oxide synthase. Br J Pharmacol. 116:2845–2851. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ekstedt M, Franzén LE, Mathiesen UL,
Thorelius L, Holmqvist M, Bodemar G and Kechagias S: Long-term
follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology. 44:865–873. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chitturi S and Farrell GC:
Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis.
21:27–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jansen PL: Non-alcoholic steatohepatitis.
Eur J Gastroenterol Hepatol. 16:1079–1085. 2004. View Article : Google Scholar
|
|
17
|
McClain CJ, Mokshagundam SP, Barve SS, et
al: Mechanisms of non-alcoholic steatohepatitis. Alcohol. 34:67–79.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bonnefont-Rousselot D, Ratziu V, Giral P,
Charlotte F, Beucler I and Poynard T; Lido Study Group. Blood
oxidative stress markers are unreliable markers of hepatic
steatosis. Aliment Pharmacol Ther. 23:91–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Albano E: Free radical mechanisms in
immune reactions associated with alcoholic liver disease. Free
Radic Biol Med. 32:110–114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim F, Pham M, Maloney E, Rizzo NO, Morton
GJ, Wisse BE, Kirk EA, Chait A and Schwartz MW: Vascular
inflammation, insulin resistance, and reduced nitric oxide
production precede the onset of peripheral insulin resistance.
Arterioscler Thromb Vasc Biol. 28:1982–1988. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guilherme A, Virbasius JV, Puri V and
Czech MP: Adipocyte dysfunctions linking obesity to insulin
resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 9:367–377.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poniachik J, Mancilla C, Contreras J,
Csendes A, Smok G, Cavada G, Rojas J, et al: Obesity: risk factor
for steatohepatitis and hepatic fibrosis. Rev Med Chil.
130:731–736. 2002.(In Spanish).
|
|
23
|
Larter CZ, Yeh MM, Haigh WG, Williams J,
Brown S, Bell-Anderson KS, Lee SP and Farrell GC: Hepatic free
fatty acids accumulate in experimental steatohepatitis: role of
adaptive pathways. J Hepatol. 48:638–647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laurent A, Nicco C, Tran Van Nhieu J,
Borderie D, Chéreau C, Conti F, et al: Pivotal role of superoxide
anion and beneficial effect of antioxidant molecules in murine
steatohepatitis. Hepatology. 39:1277–1285. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Montfort C, Matias N, Fernandez A,
Fucho R, Conde de la Rosa L, Martinez-Chantar ML, et al:
Mitochondrial GSH determines the toxic or therapeutic potential of
superoxide scavenging in steatohepatitis. J Hepatol. 57:852–859.
2012.PubMed/NCBI
|
|
26
|
Böhm T, Berger H, Nejabat M, Riegler T,
Kellner F, Kuttke M, Sagmeister S, Bazanella M, et al: Food-derived
peroxidized fatty acids may trigger hepatic inflammation: a novel
hypothesis to explain steatohepatitis. J Hepatol. 59:563–570.
2013.PubMed/NCBI
|
|
27
|
Liu VW and Huang PL: Cardiovascular roles
of nitric oxide: a review of insights from nitric oxide synthase
gene disrupted mice. Cardiovasc Res. 77:19–29. 2008.PubMed/NCBI
|
|
28
|
Tateya S, Rizzo NO, Handa P, et al:
Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell
activation and hepatic insulin resistance induced by high-fat
feeding. Diabetes. 60:2792–2801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Friedmann SL: Molecular regulation of
hepatic fibrosis, an integrated cellular response to tissue injury.
J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boisclair J, Doré M, Beauchamp G,
Chouinard L and Girard C: Characterization of the inflammatory
infiltrate in canine chronic hepatitis. Vet Pathol. 38:628–635.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bataller R and Brenner D: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View
Article : Google Scholar
|
|
32
|
Mekonnen GA, Ijzer J and Nederbragt H:
Tenascin-C in chronic canine hepatitis: immunohistochemical
localization and correlation with necro-inflammatory activity,
fibrotic stage, and expression of alpha-smooth muscle actin,
cytokeratin 7, and CD3+ cells. Vet Pathol. 44:803–813.
2007. View Article : Google Scholar
|
|
33
|
Bedossa P and Paradis V: Liver
extracellular matrix in health and disease. J Pathol. 200:504–515.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guyot C, Lepreux S, Combe C, Doudnikoff E,
Bioulac-Sage P, Balabaud C and Desmoulière A: Hepatic fibrosis and
cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int
J Biochem Cell Biol. 38:135–151. 2006.PubMed/NCBI
|
|
35
|
Hinz B, Phan SH, Thannickal VJ, Galli A,
Bochaton-Piallat M and Gabbiani G: The myofibroblast: one function,
multiple origins. Am J Pathol. 170:1807–1816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ijzer J, Roskams T, Molenbeek RF, Ultee T,
Penning LC, Rothuizen J and van den Ingh TS: Morphological
characterization of portal myofibroblasts and hepatic stellate
cells in the normal dog liver. Comp Hepatol. 5:72006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lever R and Page CP: Non-anticoagulant
effects of heparin: an overview. Handb Exp Pharmacol. 207:281–305.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mu E, Ding R, An X, Li X, Chen S and Ma X:
Heparin attenuates lipopolysaccharide-induced acute lung injury by
inhibiting nitric oxide synthase and TGF-β/Smad signaling pathway.
Thromb Res. 129:479–485. 2012.
|
|
39
|
Horstman DJ, Fischer LG, Kouretas PC,
Hannan RL and Rich GF: Role of nitric oxide in heparin-induced
attenuation of hypoxic pulmonary vascular remodeling. J Appl
Physiol (1985). 92:2012–2018. 2002.PubMed/NCBI
|
|
40
|
Ding R, Zhao D, Guo B, Zhang Z and Ma X:
Treatment with unfractionated heparin attenuates coagulation and
inflammation in endotoxemic mice. Thromb Res. 128:e160–e165. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tokuyama Y, Nozaki O and Kanatsuka A: A
patient with subcutaneous-insulin resistance treated by insulin
lispro plus heparin. Diabetes Res Clin Pract. 54:209–212. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fiorucci S, Antonelli E, Distrutti E,
Severino B, Fiorentina R, Baldoni M, et al: PAR1 antagonism
protects against experimental liver fibrosis. Role of proteinase
receptors in stellate cell activation. Hepatology. 39:365–375.
2004. View Article : Google Scholar : PubMed/NCBI
|
